Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4411-4420

  Chang, Hsiu Hao ^a,e,i   Lee, Hsinyu ^b   Hu, Ming Kuan ^f   Tsao, Po Nien ^a   Juan, Hsueh Fen ^b   Huang, Min Chuan ^e   Shih, Yu Yin ^b,c   Wang, Bo Jeng ^b,c   Jeng, Yung Ming ^a   Chang, Christina Ling ^h   Huang, Shiu Feng ⁱ   Tsay, Yeou Guang ^d   Hsieh, Fon Jou ^e   Lin, Kai Hsin ^a,e,g   Hsu, Wen Ming ^a,g   Liao, Yung Feng ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^g Childhood Cancer Foundation   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

ⁱ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; GAMMA SECRETASE; NOTCH1 RECEPTOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR XENOGRAFT; WESTERN BLOTTING;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTHRACENES; BLOTTING, WESTERN; CALRETICULIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NEUROBLASTOMA; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, NOTCH1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956256647     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3360     Document Type: Article

References (45)

1. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep 2009;11:431-8.
2. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
4. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 2009;27:1007-13.
5. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
6. Sjolund J, Johansson M, Manna S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2008;118:217-28.
7. Pahlman S, Stockhausen MT, Fredlund E, Axelson H. Notch signaling in neuroblastoma. Semin Cancer Biol 2004;14:365-73.
8. Axelson H. The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett 2004;204:171-8.
9. Revet I, Huizenga G, Chan A, et al. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Δ-Notch pathway in neuroblastoma. Exp Cell Res 2008;314:707-19.
10. Funahashi Y, Hernandez SL, Das I, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 2008;68:4727-35.
11. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (New York, NY) 1999;284:770-6.
12. Morrison SJ, Perez SE, Qiao Z, et al. Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell 2000;101:499-510.
13. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003;22:6598-608.
14. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006;6:347-59.
15. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67.
16. Grynfeld A, Pahlman S, Axelson H. Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1. Int J Cancer 2000;88:401-10.
17. Levy OA, Lah JJ, Levey AI. Notch signaling inhibits PC12 cell neurite outgrowth via RBP-J-dependent and -independent mechanisms. Dev Neurosci 2002;24:79-88.
18. Franklin JL, Berechid BE, Cutting FB, et al. Autonomous and non-autonomous regulation of mammalian neurite development by Notch1 and Δ1. Curr Biol 1999;9:1448-57.
19. Liao YF, Wang BJ, Hsu WM, et al. Unnatural amino acid-substituted (hydroxyethyl)urea peptidomimetics inhibit γ-secretase and promote the neuronal differentiation of neuroblastoma cells. Mol Pharmacol 2007;71:588-601.
20. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma - a novel independent prognostic factor. Ann Oncol 2005;16:314-21.
21. Johnson RJ, Liu N, Shanmugaratnam J, Fine RE. Increased calreticulin stability in differentiated NG-108-15 cells correlates with resistance to apoptosis induced by antisense treatment. Brain Res Mol Brain Res 1998;53:104-11.
22. Xiao G, Chung TF, Fine RE, Johnson RJ. Calreticulin is transported to the surface of NG108-15 cells where it forms surface patches and is partially degraded in an acidic compartment. J Neurosci Res 1999;58:652-62.
23. Xiao G, Chung TF, Pyun HY, Fine RE, Johnson RJ. KDEL proteins are found on the surface of NG108-15 cells. Brain Res Mol Brain Res 1999;72:121-8.
24. Almgren MA, Henriksson KC, Fujimoto J, Chang CL. Nucleoside diphosphate kinase A/nm23-1 promotes metastasis of NB69-derived human neuroblastoma. Mol Cancer Res 2004;2:387-94.
25. Ossewaarde JM, de Vries A, Bestebroer T, Angulo AF. Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chlamydia sp. strains. Appl Environ Microbiol 1996;62:328-31.
26. Dovey HF, John V, Anderson JP, et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 2001;76:173-81.
27. Hsu WM, Lee H, Juan HF, et al. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin Cancer Res 2008;14:6237-45.
28. Ordentlich P, Lin A, Shen CP, et al. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol Cell Biol 1998;18:2230-9.
29. Zecchini V, Brennan K, Martinez-Arias A. An activity of Notch regulates JNK signalling and affects dorsal closure in Drosophila. Curr Biol 1999;9:460-9.
30. Kim JW, Kim MJ, Kim KJ, et al. Notch interferes with the scaffold function of JNK-interacting protein 1 to inhibit the JNK signaling pathway. Proc Natl Acad Sci U S A 2005;102:14308-13.
31. Kopan R, Schroeter EH, Weintraub H, Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A 1996;93:1683-8.
32. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (New York, NY) 2002;298:1911-2.
33. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 1999;22:667-76.
34. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev 1999;89:115-24.
35. Heasley LE, Han SY. JNK regulation of oncogenesis. Mol Cell 2006;21:167-73.
36. Srinivasan V, Tatu U, Mohan V, Balasubramanyam M. Molecular convergence of hexosamine biosynthetic pathway and ER stress leading to insulin resistance in L6 skeletal muscle cells. Mol Cell Biochem 2009;328:217-24.
37. Kim YM, Kim HJ, Song EJ, Lee KJ. Glucuronic acid is a novel inducer of heat shock response. Mol Cell Biochem 2004;259:23-33.
38. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004;14:779-86.
39. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALLXII/ECOG 2993). Blood 2009;114:5136-45.
40. Wang M, Xue L, Cao Q, et al. Expression of Notch1, Jagged1 and β-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 2009;56:533-41.
41. Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009;27:4352-6.
42. Reedijk M, Odorcic S, Zhang H, et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 2008;33:1223-9.
43. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
44. Castleberry RP. Neuroblastoma. Eur J Cancer 1997;33:1430-7, discussion 7-8.
45. Pear WS, Aster JC. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling. Curr Opin Hematol 2004;11:426-33.